Cancer Commons is collaborating with Cureus to bring you the first Exceptional Responders in Oncology Publishing Competition. We are seeking challenging cases in which patients exhibited unexpected or exceptional responses (positive or negative) to therapy.
We are particularly interested in the treatment options you considered, your clinical/scientific rationale for selecting the treatment, and the patient outcome. Our goal is to share the results with other patients and oncologists who might benefit, so that positive experiences can be quickly explored and negative experiences quickly avoided.
COMPETITION ENTRY IS NOW CLOSED.
The entry period is now closed. Competition entries appear below as they are published. Now is your chance to score and discuss these articles. Remember, the article with the highest SIQ score will be chosen as the competition winner!
Eligible entries are limited to individual patient case reports, submitted and formatted via the template-driven, self-publishing Cureus platform. Case reports should aim for a 1,000 – 1,200 word target, with a 2,500 word maximum. A limit of five references is strongly encouraged (10 reference maximum).
Competition entry and case report submission is entirely free. All submitted work must be previously unpublished. For additional information on publishing with Cureus, please see our Author Guide.
Statement of Independence
- Cureus Publishing Competitions are intended to encourage medical discovery, document clinical experiences – be they positive, negative, or neutral - and foster broader educational outreach through open access publication that is free to both authors and readers.
- Article submissions must adhere to the described “call for articles” and are open to any and all related manufacturer or vendor technologies.
- As a firewall to ensure objective and credible science, article selection, editorial review, peer review and publication are strictly independent of sponsoring company.
- Winning articles are determined exclusively via peer review panel and community crowdsourced scoring. Neither sponsoring company, nor Cureus, can determine competition outcome.
- All clinical studies must be compliant with applicable regulatory, ethics / IRB, and other rules governing protection of human subjects.
- All non-clinical studies must be compliant with applicable AAUC, AAALAC, and other related regulations.
- This program is not intended to promote or otherwise encourage unapproved, un-cleared use of products or any product for unapproved new use.
- This program in no way promotes or purports to encourage any research that is not in compliance with any local, federal, or other applicable governing laws.
A single $3,000 USD monetary prize will be awarded to the published case report that receives the highest Cureus SIQ™ (Scholarly Impact Quotient™) score. SIQ is Cureus’ unique post-publication peer-review process used to judge article importance via the collective intelligence of the Cureus community-at-large. The SIQ algorithm measures community engagement and scoring for article clarity and rationale, clinical importance, study design and methods, data analysis, novelty of conclusions and quality of presentation.
Eligible case reports must receive a minimum of 20 scores. (A Cureus user can assign only one score per article.) As engagement and scoring is critical to winning, authors are highly encouraged to share their published articles via social media and email.
To ensure that submitted work receives the exposure it deserves, all case reports published as part of this competition will be indexed in PubMed Central and distributed to large communities of oncologists around the globe.
COMPETITION ENTRY IS NOW CLOSED.
Peer Review Panel
We’ve assembled a world-class peer review panel to review all submitted case reports. Click on a reviewer name to learn more.
Article analysis and commentary performed by the peer review panel are strictly independent of the sponsor.
BJ RimelM.D., Assistant Professor | Obstetrics and Gynecology
Obstetrics and Gynecology, Samuel Oschin Comprehensive Cancer Institute
David E. FisherM.D., Ph.D. | Dermatology
Department of Dermatology, Harvard Medical School; Melanoma Center, Massachusetts General Hospital
Heinz-Josef LenzM.D., Professor | Oncology
Adult Oncology, USC Norris Comprehensive Cancer Center
Ravi SalgiaM.D., Ph.D., Professor | Dermatology
Pathology and Dermatology, The University of Chicago Medicine
Kevin KnopfM.D., M.P.H. | Oncology
Medical Oncology Department, Sutter Pacific Medical Center Research Institute
Charles S. CobbsM.D. | Neurological Surgery
The Ben & Catherine Ivy Center for Advanced Brain Tumor Treatment, Swedish Neuroscience Institute
Lincoln NadauldM.D., Ph.D. | Oncology
Cancer Genomics, Intermountain Healthcare
Jimmy CaudellM.D., Ph.D. | Radiation Oncology
Department of Radiation Oncology, Moffitt Cancer Center
Peter K. Bryant-GreenwoodM.D., M.B.A. | Pathology
Clinical and Translational Research, The University of Hawaii Cancer Center
Emma ShtivelmanPh.D. | Neurology
Mae ZakhourM.D. | Obstetrics and Gynecology
Gynecologic Oncology, Cedars-Sinai Medical Center
- Thursday, October 22, 2015 – Competition begins; case reports may now be submitted.
- Monday, November 23, 2015 – Case report submission deadline @ 11:59 pm PT.
- Monday, December 14, 2015 – Peer review of all eligible case reports concludes @ 11:59 pm PT.
- Monday, January 18, 2016 – Community post-publication review (SIQ) ends @ 5 pm PT.
- Monday, January 25, 2016 – Winning case report announced; the winning author(s) will be contacted and formally announced on the Cureus website.